Crohn's Disease and Colitis Trial, Not Yet Recruiting NCT06833021 Sponsor: IRCCS San Raffaele Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Not Yet Recruiting

NCT06833021
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 or older, male or female, who have been diagnosed with one of the following conditions: colitis-associated cancer (CAC), colorectal cancer (CRC), diverticulitis, ischaemic colitis (IC), or Crohn's disease (CD), and who previously had a tissue sample taken by endoscopy or had surgery as part of their standard medical care between 2021 and 2024.
  • People with no recorded history of Hepatitis B virus (HBV) infection.
  • People who have already signed a consent form allowing their medical data to be used for future scientific research.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People under 18 years of age.
  • Adults aged 18 or older, male or female, diagnosed with CAC, CRC, diverticulitis, IC, or Crohn's disease who have a recorded history of Hepatitis B virus (HBV) infection.
  • People who have not signed a consent form allowing their medical data to be used for future scientific research.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Silvio Danese, PhD-MD, IRCCS San Raffaele

Phone: +39 0226432807

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
IRCCS San Raffaele
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
1 April 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

To define HBx as a predictive biomarker of CAC in UC patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov